Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Down 8.1% – Should You Sell?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) shares dropped 8.1% during trading on Wednesday . The stock traded as low as $20.16 and last traded at $19.9160. Approximately 78,397 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 329,817 shares. The stock had previously closed at $21.66.

Analysts Set New Price Targets

KMTS has been the subject of several research reports. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. Finally, The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $27.40.

Kestra Medical Technologies Stock Performance

The stock’s 50-day moving average price is $21.34 and its 200-day moving average price is $24.18. The company has a current ratio of 7.32, a quick ratio of 7.32 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.27 billion and a P/E ratio of -5.51.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The business had revenue of $24.55 million during the quarter. The business’s quarterly revenue was up 62.7% compared to the same quarter last year. As a group, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current year.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $20.04, for a total value of $300,600.00. Following the transaction, the insider directly owned 349,786 shares in the company, valued at approximately $7,009,711.44. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 45,000 shares of company stock valued at $988,650. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Kestra Medical Technologies in the 3rd quarter worth about $562,000. Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter worth about $9,282,000. Next Century Growth Investors LLC increased its holdings in shares of Kestra Medical Technologies by 154.5% in the 4th quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company’s stock worth $12,354,000 after acquiring an additional 282,832 shares during the period. Eventide Asset Management LLC increased its holdings in shares of Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the period. Finally, Brown Advisory Inc. increased its holdings in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after acquiring an additional 428,996 shares during the period.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.